血清补体C3、C4检验在多发性骨髓瘤患者病情评估中的作用分析

Analysis of the Role of Serum Complement C3 and C4 Tests in the Disease Assessment of Multiple Myeloma Patients

目的探讨对多发性骨髓瘤患者通过血清补体C3、C4检验进行病情评估的临床价值。方法选取2019年2月—2021年5月常熟市医学检验所中的68例多发性骨髓瘤患者作为研究组;选取2018年2月—2021年5月本医学检验所中的68名健康志愿者作为参照组。检验并对比两组研究对象的血清补体C3、C4水平,同时,对比不同ISS分期患者血清补体C3、C4水平。结果研究组血清补体C3(3.19±0.79)g/L、C4(0.52±0.16)g/L较参照组血清补体C3(1.13±0.25)g/L、C4(0.29±0.12)g/L均明显提升,差异有统计学意义(t=20.500、9.483,P<0.05);ISS分期Ⅰ期患者血清补体C3(1.82±0.52)g/L、C4(0.29±0.12)g/L均低于Ⅱ期、Ⅲ期患者,差异有统计学意义(P<0.05)。结论多发性骨髓瘤疾病患者自身血清补体C3、C4水平会呈现出显著升高,通过检测血清补体C3、C4水平,可就多发性骨髓瘤患病情况加以明确。并且伴随ISS分期的增加,患者血清补体C3、C4水平也会随之升高。

Objective To explore the clinical value of evaluating the condition of patients with multiple myeloma by testing serum complement C3 and C4.Methods 68 patients with multiple myeloma from Changshu Medical Labora⁃tory from February 2019 to May 2021 were selected as the study group;68 healthy volunteers from the Institute of Medical Laboratory from February 2018 to May 2021 were selected as the reference group.Tested and compared the levels of serum complement C3 and C4 of the two groups of subjects,and compared the levels of serum complement C3 and C4 of patients with different ISS stages.Results The serum complement C3(3.19±0.79)g/L and C4(0.52±0.16)g/L in the study group were significantly higher than those in the control group(1.13±0.25)g/L and C4(0.29±0.12)g/L,and the difference was statistically significant(t=20.500,9.483,P<0.05).The levels of serum complement C3(1.82±0.52)g/L and C4(0.29±0.12)g/L in patients with ISS stage I were significantly lower than those in patients with stage II and stage III,and the difference was statistically significant(P<0.05).Conclusion The level of serum complement C3 and C4 in patients with multiple myeloma disease will show a significant increase.By detecting the level of serum complement C3 and C4,can clarify the prevalence of multiple myeloma.And with the increase of ISS stage,the level of serum complement C3 and C4 will also increase.